A systematic review was conducted to examine the potential impact of new molecular‐based screening tests on CRC incidence and mortality.

Programs that support patients in the screening process or mail stool test kits to their homes are most effective at boosting colorectal cancer screening rates.

ACG posed several key questions and developed practical recommendations for practice providers. The recommendations were crafted through a focused literature search and supplemented by existing ...

The updated ACS guideline adds 3 tests to its recommended screening options, reflecting advances in disease detection and a broader public health effort to expand access and lower barriers to ...

Updated ACS guidance suggests use in those who decline other options ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

MADISON, Wis., April 28, 2021 /PRNewswire/ -- Exact Sciences (NASDAQ: EXAS) today announces study results published in Mayo Clinic Proceedings showing that Cologuard (mt-sDNA) is the most ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — Multimodal circulating tumor DNA blood-based colorectal cancer screening tests may have clinically ...

Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood ...